Next Article in Journal
Why Immunotherapy Fails in Multiple Myeloma
Previous Article in Journal
The Management of Hematologic Patients with Bloodstream Infections Due to Multi-Drug Resistant Bacteria: Where Do We Stand? From Antibacterial Prophylaxis to the Treatment of Septic Shock
Article

Indoleamine 2,3-Dioxygenase Activity Is Increased in Myelodysplastic Syndrome Patients

1
First Department of Internal Medicine, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan
2
Department of Hematology, Matsunami General Hospital, Gifu 501-6062, Japan
3
Department of Disease Control and Prevention, Fujita Health University Graduate School of Health Science, Toyoake 470-1192, Japan
*
Author to whom correspondence should be addressed.
Received: 20 October 2020 / Revised: 26 November 2020 / Accepted: 10 December 2020 / Published: 11 December 2020
(This article belongs to the Section Chronic Myeloid Disease)
Tryptophan (TRP) metabolism via the indoleamine 2,3-dioxygenase (IDO) subset of the kynurenine (KYN) pathway is one of the most important mechanisms of immune escape in cancer. TRP is converted into several biologically active KYN metabolites. However, the role of KYN metabolic products and related enzymes has not been clarified in patients with hematological malignant tumors. Here, we examined the serum concentrations of TRP, KYN, and the KYN metabolites kynurenic acid, anthranilic acid, and 3-hydroxyanthranilic acid in 157 patients stratified into five different hematological malignant tumors. KYN was the most abundant product of the TRP metabolic pathway among all five diagnostic categories. Serum KYN was increased in myelodysplastic syndrome (MDS) patients. The KYN/TRP ratio was significantly higher in MDS patients than in acute myeloid leukemia patients. In conclusion, IDO activity is increased in MDS patients, and IDO inhibitors might represent a new therapeutic approach for MDS treatment. View Full-Text
Keywords: tryptophan metabolism; IDO; MDS tryptophan metabolism; IDO; MDS
Show Figures

Figure 1

MDPI and ACS Style

Yamaguchi, K.; Ninomiya, S.; Matsumoto, T.; Nakamura, N.; Nakamura, H.; Kitagawa, J.; Kanemura, N.; Hara, T.; Fujigaki, S.; Yamamoto, Y.; Saito, K.; Tsurumi, H.; Shimizu, M. Indoleamine 2,3-Dioxygenase Activity Is Increased in Myelodysplastic Syndrome Patients. Hemato 2020, 1, 77-85. https://0-doi-org.brum.beds.ac.uk/10.3390/hemato1020011

AMA Style

Yamaguchi K, Ninomiya S, Matsumoto T, Nakamura N, Nakamura H, Kitagawa J, Kanemura N, Hara T, Fujigaki S, Yamamoto Y, Saito K, Tsurumi H, Shimizu M. Indoleamine 2,3-Dioxygenase Activity Is Increased in Myelodysplastic Syndrome Patients. Hemato. 2020; 1(2):77-85. https://0-doi-org.brum.beds.ac.uk/10.3390/hemato1020011

Chicago/Turabian Style

Yamaguchi, Kimihiro, Soranobu Ninomiya, Takuro Matsumoto, Nobuhiko Nakamura, Hiroshi Nakamura, Junichi Kitagawa, Nobuhiro Kanemura, Takeshi Hara, Suwako Fujigaki, Yasuko Yamamoto, Kuniaki Saito, Hisashi Tsurumi, and Masahito Shimizu. 2020. "Indoleamine 2,3-Dioxygenase Activity Is Increased in Myelodysplastic Syndrome Patients" Hemato 1, no. 2: 77-85. https://0-doi-org.brum.beds.ac.uk/10.3390/hemato1020011

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop